Rankings
▼
Calendar
TGTX Q4 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+6007.9% YoY
Gross Profit
$2M
91.0% margin
Operating Income
-$93M
-4004.6% margin
Net Income
-$93M
-4021.5% margin
EPS (Diluted)
$-0.70
QoQ Revenue Growth
+14.3%
Cash Flow
Operating Cash Flow
-$87M
Free Cash Flow
-$87M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$380M
Total Liabilities
$142M
Stockholders' Equity
$237M
Cash & Equivalents
$299M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$38,000
+6007.9%
Gross Profit
$2M
-$68,000
+3204.4%
Operating Income
-$93M
-$87M
-7.1%
Net Income
-$93M
-$88M
-5.8%
Revenue Segments
Product revenue, net
$2M
98%
License revenue
$38,000
2%
← FY 2021
All Quarters
Q1 2022 →